← back to search

Isabella Heuser

Charité - Universitätsmedizin Berlin · DE
Area of research
Psychiatry and Mental health · Behavioral Neuroscience
Research interest
Research interests include Stress Responses and Cortisol, Treatment of Major Depression, Tryptophan and brain disorders, and Schizophrenia research and treatment.
h-index
78
citations
30,600
works
481
NIH funding
primary concept
email

Recent publications

Acute and Chronic Macrophage Differentiation Modulates TREM2 in a Personalized Alzheimer’s Patient-Derived Assay
Cellular and Molecular Neurobiology 2023cited by 7position: middledoi
Effect of Minocycline on Depressive Symptoms in Patients With Treatment-Resistant Depression
JAMA Network Open 2022cited by 88position: lastdoi
M1/M2 polarization in major depressive disorder: Disentangling state from trait effects in an individualized cell-culture-based approach
Brain Behavior and Immunity 2021cited by 33position: middledoi
Antidepressant and neurocognitive effects of serial ketamine administration versus ECT in depressed patients
Journal of Psychiatric Research 2020cited by 68position: middledoi
A simple approach to optimum pool size for pooled SARS-CoV-2 testing
International Journal of Infectious Diseases 2020cited by 47position: middledoi
Gray matter volume of rostral anterior cingulate cortex predicts rapid antidepressant response to ketamine
European Neuropsychopharmacology 2020cited by 27position: middledoi
Clozapine modulates retinoid homeostasis in human brain and normalizes serum retinoic acid deficit in patients with schizophrenia
Molecular Psychiatry 2020cited by 21position: middledoi
Minocycline alters behavior, microglia and the gut microbiome in a trait-anxiety-dependent manner
Translational Psychiatry 2019cited by 151position: middledoi
Anxiety during ketamine infusions is associated with negative treatment responses in major depressive disorder
European Neuropsychopharmacology 2019cited by 65position: middledoi
Remission in schizophrenia — What are we measuring? Comparing the consensus remission criteria to a CGI-based definition of remission and to remission in major depression
Schizophrenia Research 2019cited by 12position: middledoi
Inhibition of monoamine oxidase activity by repetitive transcranial magnetic stimulation: implications for inter-train interval and frequency
European Archives of Psychiatry and Clinical Neuroscience 2018cited by 7position: middledoi
Combined treatment with memantine and galantamine‐CR compared with galantamine‐CR only in antidementia drug naïve patients with mild‐to‐moderate Alzheimer's disease
Alzheimer s & Dementia Translational Research & Clinical Interventions 2015cited by 31position: lastdoi
The use of biomarkers for the etiologic diagnosis of MCI in Europe: An EADC survey
Alzheimer s & Dementia 2014cited by 74position: middledoi
What are residual symptoms in schizophrenia spectrum disorder? Clinical description and 1-year persistence within a naturalistic trial
European Archives of Psychiatry and Clinical Neuroscience 2014cited by 38position: middledoi
What are depressive symptoms in acutely ill patients with schizophrenia spectrum disorder?
European Psychiatry 2014cited by 22position: middledoi
Cognitive-Behavioral Therapy as Continuation Treatment to Sustain Response After Electroconvulsive Therapy in Depression: A Randomized Controlled Trial
Biological Psychiatry 2013cited by 119position: middledoi
Predictors of Relapse in the Year After Hospital Discharge Among Patients With Schizophrenia
Psychiatric Services 2012cited by 102position: middledoi
The Role of Variation at AβPP, PSEN1, PSEN2, and MAPT in Late Onset Alzheimer's Disease
Journal of Alzheimer s Disease 2012cited by 59position: middledoi
No consistent evidence for association between mtDNA variants and Alzheimer disease
Neurology 2012cited by 53position: middledoi
Evaluating Depressive Symptoms in Schizophrenia: A Psychometric Comparison of the Calgary Depression Scale for Schizophrenia and the Hamilton Depression Rating Scale
Psychopathology 2012cited by 50position: middledoi
Insight in schizophrenia–course and predictors during the acute treatment phase of patients suffering from a schizophrenia spectrum disorder
European Psychiatry 2012cited by 32position: middledoi
Response trajectories in “real-world” naturalistically treated schizophrenia patients
Schizophrenia Research 2012cited by 31position: middledoi

Grants

No grants ingested yet.

Frequent collaborators

Julian Hellmann‐Regen · German Centre for Cardiovascular Research7 papers (2018–2023)Rebecca Schennach · Ludwig-Maximilians-Universität München6 papers (2012–2014)Stefan Klingberg · University of Tübingen6 papers (2012–2014)Max Schmauß · Ludwig-Maximilians-Universität München6 papers (2012–2014)Gerd Laux · Johannes Gutenberg University Mainz6 papers (2012–2014)Lutz Schmidt · Johannes Gutenberg University Mainz6 papers (2012–2014)Herbert Pfeiffer · Ludwig-Maximilians-Universität München6 papers (2012–2014)Markus Jäger · Ludwig-Maximilians-Universität München6 papers (2012–2014)Matthias Lemke · Johannes Gutenberg University Mainz6 papers (2012–2014)Dieter Naber · Ludwig-Maximilians-Universität München6 papers (2012–2014)Michael Riedel · Institut für Höhere Studien - Institute for Advanced Studies (IHS)6 papers (2012–2014)Francesca Regen · Charité - Universitätsmedizin Berlin6 papers (2013–2021)Joachim Klosterkötter · Ludwig-Maximilians-Universität München6 papers (2012–2014)Markus Gastpar · Ludwig-Maximilians-Universität München6 papers (2012–2014)Wolfgang Gäebel · Ludwig-Maximilians-Universität München6 papers (2012–2014)Malek Bajbouj · Klinik und Poliklinik für Psychiatrie und Psychotherapie5 papers (2013–2020)Hans‐Jürgen Möller · University of Regensburg5 papers (2012–2015)Eckart Rüther · Ludwig-Maximilians-Universität München5 papers (2012–2015)Florian Seemüller · University of Regensburg5 papers (2012–2014)Michael Obermeier · Ludwig-Maximilians-Universität München4 papers (2012–2014)